Neftaly: The Use of Biomarkers to Inform Health System Planning and Policy

Introduction

In an era of data-driven healthcare, biomarkers—objective indicators of biological and pathological processes—have become essential tools for guiding smarter, more responsive, and more equitable health system planning.

At Neftaly, we advocate for the strategic use of biomarker data to shape policies that reflect real population health needs, optimize resource allocation, and support evidence-based decision-making.

---

Why Biomarkers Matter for Policy and Planning

Traditional health planning often relies on lagging indicators such as mortality rates or hospitalization data. While valuable, these measures frequently reflect health outcomes after system failure.

Biomarkers, on the other hand, provide early, precise, and actionable information that can be used to:

• Predict disease risk at a population level
• Track disease trends in real time
• Evaluate health system performance and impact
• Design targeted, cost-effective interventions

---

Key Policy Areas Where Biomarkers Add Value

1. Strategic Health Planning

• Use biomarkers to map disease burden and anticipate future health needs (e.g., prevalence of pre-diabetic biomarkers to plan NCD strategies).
• Identify high-risk populations through genetic or biochemical markers to tailor prevention programs.

2. Resource Allocation and Budgeting

• Biomarker trends can inform data-driven funding decisions for diagnostics, medicines, or workforce deployment.
• Improve cost-effectiveness by identifying which populations will benefit most from interventions.

3. Disease Prevention and Early Intervention

• Policies can be informed by biomarker-based screening programs (e.g., cervical cancer via HPV DNA, liver disease via ALT levels).
• Enable earlier and more efficient investments in prevention—reducing long-term health costs.

4. Monitoring and Evaluation (M&E)

• Biomarkers serve as objective indicators for tracking health outcomes, treatment response, and intervention success.
• Enhance national health information systems by integrating biomarker surveillance as a core M&E tool.

5. Emergency Preparedness and Response

• Biomarker surveillance systems can detect public health threats (e.g., emerging infections) earlier than conventional reporting.
• Enable rapid policy shifts and resource mobilization during epidemics or environmental health crises.

---

Best Practices for Biomarker-Driven Policy Development

1. Align Biomarker Use with National Health Priorities
   Identify relevant biomarkers that address key disease burdens and policy goals.
2. Build Strong Data Ecosystems
   Integrate biomarker data into national health information systems for continuous and real-time decision-making.
3. Ensure Equity in Data Collection and Use
   Collect data across diverse populations to avoid biases in policy outcomes.
4. Support Cross-Sector Collaboration
   Involve stakeholders from research, clinical practice, and public health in shaping biomarker-informed policies.
5. Develop Ethical and Legal Frameworks
   Protect individuals’ rights by implementing clear policies around biomarker data use, consent, and confidentiality.

---

Neftaly’s Role

At Neftaly, we work with partners to:

• Design policy frameworks that incorporate biomarkers into planning cycles
• Train policymakers and technical teams on interpreting and using biomarker data
• Facilitate data integration across clinical, research, and public health systems
• Conduct strategic assessments to evaluate how biomarker use improves policy outcomes

---

Conclusion

Biomarkers are no longer just clinical tools—they are policy enablers. When used strategically, they help governments plan better, respond faster, and deliver more equitable health outcomes.